Lymphoma: all 5,624 studies
Page 33 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?CompletedNCT03265574Phase 3
- Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0Status unknownNCT03265158
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsStatus unknownNCT03265106Phase 1/2
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell LymphomaStatus unknownNCT03261349Phase 2
- Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma SurvivorshipCompletedNCT03260855Not applicable
- Dietary Milled Seed Mix in Patients With Non-Hodgkin LymphomaStatus unknownNCT03260231Not applicable
- Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
- Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLCompletedNCT03259529Phase 1/2
- Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell LymphomaStatus unknownNCT03258047Phase 2
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
- B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell LymphomaCompletedNCT03246750Phase 1/2
- Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHLStatus unknownNCT03245905Phase 2
- Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3AActive, not recruitingNCT03245021Phase 1
- Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood TransplantationStatus unknownNCT03244930Phase 2
- Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyActive, not recruitingNCT03244176Early Phase 1
- To Decrease Fatigue With Light TherapyCompletedNCT03242902Phase 3
- Durvalumab in DLBCL After Autologous TransplantWithdrawnNCT03241017Phase 2
- Pedometer Activity Monitoring After ASCTCompletedNCT03238599Phase 2
- Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
- Constitutional Genetics in Follicular LymphomaStatus unknownNCT03234140
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCTStatus unknownNCT03229616Phase 2/3
- A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular LymphomaStatus unknownNCT03221348Phase 1
- Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03219047Early Phase 1
- A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell LymphomasCompletedNCT03218072Phase 1
- CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
- Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
- Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell LymphomaCompletedNCT03212937Phase 1
- Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCLWithdrawnNCT03212807Phase 2
- Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
- Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)CompletedNCT03211702
- Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT03208556Phase 1
- T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas PatientsStatus unknownNCT03207789
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
- Chidamide With R-CHOP Regimen for DLBCL PatientsStatus unknownNCT03201471Phase 2
- Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With NivolumabCompletedNCT03200977
- Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell LymphomaCompletedNCT03200015Phase 2
- Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell LymphomaTerminatedNCT03189836Phase 1
- First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT03188965Phase 1
- Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System LymphomaCompletedNCT03188354Not applicable
- Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or LymphomasTerminatedNCT03188328Phase 1
- Risk Adapted Therapy in Diffuse Large B Cell LymphomaStatus unknownNCT03188198Phase 2
- Brentuximab Vedotin and BeEAM High-dose Chemotherapy in LymphomasSuspendedNCT03187210Phase 1/2
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22Status unknownNCT03185494Phase 1/2
- Micro Ribosomal Nucleic Acid 155 in Non Hodgkin LymphomaCompletedNCT03185325
- A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic LymphomaCompletedNCT03181126Phase 1
- Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasActive, not recruitingNCT03179930Phase 2
- Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03174808Not applicable
- Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT03172936Phase 1
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- Study of NC-4016 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT03168035Phase 1
- Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant LymphomaStatus unknownNCT03167476
- A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaStatus unknownNCT03166878Phase 1/2
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2
- Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell LymphomasCompletedNCT03161054Phase 2
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma SubjectsStatus unknownNCT03156101Phase 1/2
- GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell LymphomaStatus unknownNCT03154918Phase 2
- Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsStatus unknownNCT03154775Phase 1
- Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownNCT03151876Phase 2
- R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCLStatus unknownNCT03151044Phase 3
- A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior TherapyStatus unknownNCT03150602Phase 4
- CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.Status unknownNCT03146533Phase 1/2
- Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to TherapyCompletedNCT03144583Phase 1
- Decision Aid Website in Helping to Make Decisions About Fertility in Participants With CancerActive, not recruitingNCT03141437Not applicable
- Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology GroupWithdrawnNCT03141398
- Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma PatientsCompletedNCT03141203Phase 1/2
- Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012WithdrawnNCT03135743
- Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
- High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCTCompletedNCT03130582
- Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
- A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedCompletedNCT03128164Phase 1
- Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma PatientsCompletedNCT03127020Phase 2
- Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaTerminatedNCT03121677Phase 1
- 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell LymphomaActive, not recruitingNCT03121456Not applicable
- PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaWithdrawnNCT03120000Phase 2
- Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory LymphomasTerminatedNCT03119467Phase 1
- CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell LymphomaStatus unknownNCT03118180Phase 1/2
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2
- ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's LymphomaCompletedNCT03107663Phase 1
- Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Status unknownNCT03105596Phase 2
- Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT03104478
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
- The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaStatus unknownNCT03101709Phase 1
- Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of AgingStatus unknownNCT03100175Not applicable
- Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CompletedNCT03098589
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20CompletedNCT03097770Phase 1/2
- Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
- Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)Status unknownNCT03091933Phase 1/2
- Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive LymphomaStatus unknownNCT03086954Phase 1
- Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
- Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL PatientsCompletedNCT03079544
- Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaTerminatedNCT03074825Phase 1
- Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT03072771Phase 1
- Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell LymphomasStatus unknownNCT03071822Phase 4